Results 151 to 160 of about 21,108 (240)

Realizing Benefits of First-in-Class Generic Entry-The Case of SGLT2 Inhibitors. [PDF]

Clin Pharmacol Ther
Gondi S, Kesselheim AS, Rome BN.
europepmc   +1 more source

SGLT‐2 Inhibitors are Associated With a Lower Risk of Multiple Myeloma

European Journal of Haematology, Volume 117, Issue 5, Page 1347-1357, November 2026.
ABSTRACT Aims We aimed to investigate drug response of sodium‐glucose transport protein‐2 inhibitors (SGLT2i) in multiple myeloma (MM), as SGLT2i have potential favorable effects on conditions related to MM. Methods We conducted a pharmacoepidemiologic study with a US nationwide health insurance claim data using Cox models to investigate the ...
Enze Liu, Anna Sun, Yuedi Yang, Jing Xu, Attaya Suvannasankha, Brian A. Walker, Pengyue Zhang   +6 more
wiley   +1 more source

Effect of Food on Balcinrenone/Dapagliflozin Pharmacokinetics and the Pharmacokinetics of Balcinrenone When Dosed with a P-gp Inhibitor. [PDF]

J Clin Pharmacol
Eriksson AL, Karsanji D, Shi AH, Parkinson J, Heijer M, Austin E, Lindmark B, Vedin-Nilsson C, Hartleib-Geschwindner J, Leonsson-Zachrisson M, Ericsson H.   +10 more
europepmc   +1 more source

The effect of mild and moderate hepatic impairment on the pharmacokinetics, safety and tolerability of balcinrenone

British Journal of Clinical Pharmacology, Volume 92, Issue 10, Page 3656-3665, October 2026.
Abstract Aim Balcinrenone (previously AZD9977) is a novel selective non‐steroidal mineralocorticoid receptor antagonist (MRA) with a differential mechanism of action relative to approved MRAs. The aim of this trial was to assess the pharmacokinetics, safety and tolerability of balcinrenone in participants with mild and moderate hepatic impairment ...
Anna L. Eriksson, Deeyen Karsanji, Bonifride Tuyishimire, Joanna Parkinson, Maria Heijer, Tadeusz Pawlik, Judith Hartleib‐Geschwindner, Maria Leonsson‐Zachrisson, Hans Ericsson   +8 more
wiley   +1 more source

Observational study on initiation of dapagliflozin in heart failure with reduced ejection fraction in the United Kingdom. [PDF]

Front Cardiovasc Med
Coombs S, Tithecott A, Thiebaud C, Chaggar P, Barker D, Banerjee P, Savage HO, Gray A, Jenkins G, Albarjas M, Hennessy L, De Courcy J, Wallis H, Dewar T, Manuell R, Barlow S, Adamsson Eryd S, Mamza JB, Morris T.   +18 more
europepmc   +1 more source

SGLT2i in heart failure: Cardiorenal mechanisms, clinical evidence and translational perspectives

Clinical and Translational Discovery, Volume 6, Issue 5, October 2026.
SGLT2 inhibitors improve heart failure outcomes through integrated cardiorenal mechanisms. In the kidney, they reduce glucose and sodium reabsorption, promoting natriuresis, osmotic diuresis and renal protection. In the heart, they enhance myocardial energetics, reduce inflammation, oxidative stress, fibrosis and adverse remodelling, resulting in fewer
Jelica Grujic‐Milanovic, Jovana Rajkovic, Radmila Novakovic, Javad Sharifi‐Rad, Daniela Calina   +4 more
wiley   +1 more source

A Comparative Evaluation of Dapagliflozin and Sulfonylureas in Patients With Type 2 Diabetes Mellitus. [PDF]

Cureus
Shaikh MS, Tripathi S, Tripathi CB, Parmar PM, Patil N, Trivedi HH.   +5 more
europepmc   +1 more source

A Case of Remarkable Improvement in Dizziness and Lightheadedness in an Elderly Patient Treated With Goshajinkigan

Traditional &Kampo Medicine, Volume 13, Issue 3, December 2026.
Akiko Kikuchi, Rie Ono, Hidehisa Saito, Shin Takayama, Tadashi Ishii   +4 more
wiley   +1 more source

An Investigation of the Factors Reducing the Use of Hospital Services: A Systematic Review

Health Science Reports, Volume 9, Issue 10, October 2026.
ABSTRACT Background and Aims Hospital service utilization has declined in many health systems due to policy shifts, limited resources, and alternative care approaches. This study aimed to systematically review the factors contributing to a reduction in the use or volume of hospital services.
Sedighe Sadat Tabatabaei Far, Majid Alizadeh, Erfan Kharazmi, Zahra Kavosi   +3 more
wiley   +1 more source

Recurrent Euglycemic Diabetic Ketoacidosis Weeks After SGLT2 Inhibitor Cessation: A Case Report. [PDF]

Case Rep Endocrinol
Mansour C, Katrib E, Mansour M, Fares M.
europepmc   +1 more source